TrialBreast cancer research and treatment2016

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.

Giancarlo Pruneri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.